Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide
| 外国特許コード | F170009182 |
|---|---|
| 整理番号 | AF12-05WO |
| 掲載日 | 2017年9月12日 |
| 出願国 | アメリカ合衆国 |
| 出願番号 | 201113579529 |
| 公報番号 | 20120322135 |
| 公報番号 | 9365637 |
| 出願日 | 平成23年2月21日(2011.2.21) |
| 公報発行日 | 平成24年12月20日(2012.12.20) |
| 公報発行日 | 平成28年6月14日(2016.6.14) |
| 国際出願番号 | JP2011053752 |
| 国際公開番号 | WO2011102517 |
| 国際出願日 | 平成23年2月21日(2011.2.21) |
| 国際公開日 | 平成23年8月25日(2011.8.25) |
| 優先権データ |
|
| 発明の名称 （英語） | Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide |
| 発明の概要（英語） |
(US9365637) The present invention provides: a novel antiviral agent containing a human antibody κ light chain, a novel human abzyme containing a human antibody κ light chain; a polynucleotide, a vector, and a transformant, encoding a human antibody κ light chain of the above; a primer set for effectively obtaining a human antibody κ light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set. |
| 特許請求の範囲（英語） |
[claim1] 1. A human abzyme comprising one of the following (a) through (f): (a) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 24; (b) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 14, and a constant domain with an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 1; (c) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 50, and a constant domain with an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 48; (d) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 35, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 33; (e) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 54, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 52; or (f) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 22, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20. [claim2] 2. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity, and anti influenza virus activity; and the variable domain consists of SEQ ID NO: 26, the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20. [claim3] 3. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity, anti influenza virus activity, and cytotoxicity against cancer cells; and the variable domain consists SEQ ID NO: 14, the constant domain has an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 1. [claim4] 4. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity and nucleolytic activity; and the variable domain consists of SEQ ID NO: 50, the constant domain has an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 48. [claim5] 5. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity; and the variable domain consists of SEQ ID NO: 35, the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 33. [claim6] 6. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity; and the variable domain consists of SEQ ID NO: 54, the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 52. [claim7] 7. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity; and the variable domain consists of SEQ ID NO: 22, the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20. [claim8] 8. A method for treating a patient of a rhabdovirus infectious disease by administering a human abzyme comprising a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, 14, 30, or 22 to the patient, wherein the administering does not comprise administering a human antibody heavy chain. [claim9] 9. A method for treating a patient of an influenza virus infectious disease by administering a human abzyme comprising a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, 14, 50, 35 or 54 to the patient. |
|
|
| 国際特許分類(IPC) |
|
| 参考情報 （研究プロジェクト等） | CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA |
日本語項目の表示
| 発明の名称 | 抗ウイルス剤、抗体酵素、プライマーセット、ポリヌクレオチドの製造方法、および、ポリペプチドの製造方法 |
|---|
※
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。
『 Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide 』に関するお問合せ
- 国立研究開発法人科学技術振興機構（ＪＳＴ） 知的財産マネジメント推進部
- URL: http://www.jst.go.jp/chizai/
-
E-mail:
- Address: 〒102-8666 東京都千代田区四番町5-3
- TEL: 03-5214-8486
- FAX: 03-5214-8417
※ 同じキーワードでJ-STORE内を検索することが出来ます。→ J-STORE内を検索
